GlassScriptPhysician profile
Sarah E Crawford
NPI 1891929824
$1,540.02
in general payments reported to CMS, 2019-2025
23 companies · $653 in 2025
The $653 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.31 · 2023: $251 · 2024: $599 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $207.67 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.82 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $137.56 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $125.10 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $117.25 | 2023-2025 | Jardiance, Mounjaro |
| Grifols USA, LLC | $102.04 | 2024-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $91.89 | 2024-2025 | Farxiga, Airsupra, Brilinta |
| Travere Therapeutics, INC. | $70.57 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $69.85 | 2024-2025 | Jynarque |
| Pfizer INC. | $58.59 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $52.42 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $51.93 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.98 | 2023 | |
| Calliditas Therapeutics US INC. | $30.32 | 2025 | Tarpeyo |
| Abbvie INC. | $28.47 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.01 | 2024 | Prolia, Evenity |
| Mallinckrodt Hospital Products INC. | $22.22 | 2025 | Terlivaz |
| Abbott Laboratories | $22.12 | 2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $20.03 | 2024 | Korlym |
| Boston Scientific Corporation | $18.80 | 2023 | Watchman Access System |
| Tris Pharma INC | $17.81 | 2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $14.85 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.72 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.